Noninvasive Imaging Estimation of Myocardial Iron Repletion Following Administration of Intravenous Iron: The Myocardial-IRON Trial
Ver/ Abrir
Impacto
Scholar |
Otros documentos de la autoría: Núñez, Julio; Miñana, Gema; Cardells, Ingrid; Palau, Patricia; Llàcer, Pau; Facila Rubio, Lorenzo; Almenar-Bonet, Luis; Lopez-Lereu, Maria Pilar; Monmeneu Menadas, Jose Vicente; Amiguet Comins, Martina; González, Jessika; Serrano, Alicia; Montagud, Vicente; López‐Vilella, Raquel; Valero, Ernesto; García-Blas, Sergio; Bodí, Vicent; de la Espriella-Juan, Rafael; Lupón, Josep; Navarro, Jorge; Górriz, José Luis; Sanchis, Juan
Metadatos
Mostrar el registro completo del ítemcomunitat-uji-handle:10234/9
comunitat-uji-handle2:10234/36080
comunitat-uji-handle3:10234/36082
comunitat-uji-handle4:
INVESTIGACIONMetadatos
Título
Noninvasive Imaging Estimation of Myocardial Iron Repletion Following Administration of Intravenous Iron: The Myocardial-IRON TrialAutoría
Fecha de publicación
2020-02-13Editor
American Heart AssociationCita bibliográfica
NÚÑEZ, Julio, et al. Noninvasive Imaging Estimation of Myocardial Iron Repletion Following Administration of Intravenous Iron: The Myocardial‐IRON Trial. Journal of the American Heart Association, 2020, vol. 9, no 4, p. e014254.Tipo de documento
info:eu-repo/semantics/articleVersión de la editorial
https://www.ahajournals.org/doi/full/10.1161/JAHA.119.014254Versión
info:eu-repo/semantics/publishedVersionPalabras clave / Materias
Resumen
Background
Intravenous ferric carboxymaltose (FCM) improves symptoms, functional capacity, and quality of life in heart failure and iron deficiency. The mechanisms underlying these effects are not fully understood. ... [+]
Background
Intravenous ferric carboxymaltose (FCM) improves symptoms, functional capacity, and quality of life in heart failure and iron deficiency. The mechanisms underlying these effects are not fully understood. The aim of this study was to examine changes in myocardial iron content after FCM administration in patients with heart failure and iron deficiency using cardiac magnetic resonance.
Methods and Results
Fifty‐three stable heart failure and iron deficiency patients were randomly assigned 1:1 to receive intravenous FCM or placebo in a multicenter, double‐blind study. T2* and T1 mapping cardiac magnetic resonance sequences, noninvasive surrogates of intramyocardial iron, were evaluated before and 7 and 30 days after randomization using linear mixed regression analysis. Results are presented as least‐square means with 95% CI. The primary end point was the change in T2* and T1 mapping at 7 and 30 days. Median age was 73 (65–78) years, with N‐terminal pro‐B‐type natriuretic peptide, ferritin, and transferrin saturation medians of 1690 pg/mL (1010–2828), 63 ng/mL (22–114), and 15.7% (11.0–19.2), respectively. Baseline T2* and T1 mapping values did not significantly differ across treatment arms. On day 7, both T2* and T1 mapping (ms) were significantly lower in the FCM arm (36.6 [34.6–38.7] versus 40 [38–42.1], P=0.025; 1061 [1051–1072] versus 1085 [1074–1095], P=0.001, respectively). A similar reduction was found at 30 days for T2* (36.3 [34.1–38.5] versus 41.1 [38.9–43.4], P=0.003), but not for T1 mapping (1075 [1065–1085] versus 1079 [1069–1089], P=0.577).
Conclusions
In patients with heart failure and iron deficiency, FCM administration was associated with changes in the T2* and T1 mapping cardiac magnetic resonance sequences, indicative of myocardial iron repletion. [-]
Proyecto de investigación
Vifor Pharma, CIBER Cardiovascular (grant numbers 16/11/00420 and 16/11/00403) ;Proyectos de Investigación de la Sección de Insuficiencia Cardiaca 2017 from Sociedad Española de Cardiología.Derechos de acceso
info:eu-repo/semantics/openAccess
Aparece en las colecciones
- MED_Articles [641]
El ítem tiene asociados los siguientes ficheros de licencia:
Excepto si se señala otra cosa, la licencia del ítem se describe como: ª 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons
Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is noncommercial and no modifications or adaptations are made